Karius Stock

Founded with the mission to revolutionize infectious disease diagnostics, Karius Inc. offers advanced solutions to improve patient outcomes. The cornerstone of their offerings, the Karius Test®, is a liquid biopsy that non-invasively detects over 1,000 pathogens from a single blood sample. This test identifies microbial cell-free DNA (mcfDNA) in the bloodstream, providing comprehensive insights into deep-seated and bloodstream infections. By utilizing cutting-edge genomics and AI technologies, Karius enhances the accuracy and speed of pathogen detection, aiding in the timely treatment of vulnerable patients. Karius's innovative approach is backed by robust clinical evidence and analytical validation, ensuring high reliability and clinical utility. The company’s proprietary machine learning algorithms and continuously updated reference genome databases enable real-time analysis of complex genomic data, offering a significant advantage in the field of infectious disease diagnostics. Based in Redwood City, California, Karius operates a CLIA-certified and CAP-accredited laboratory, adhering to high standards of clinical laboratory testing. The Karius Test® meets stringent quality and performance criteria, making it a trusted tool for healthcare professionals. Karius collaborates with biopharma partners and participates in key clinical studies, such as the PICKUP study for pneumonia detection in immunocompromised patients. These efforts highlight their commitment to advancing medical science and improving healthcare delivery. Through continuous innovation and dedication to clinical excellence, Karius strives to save lives and transform the landscape of infectious disease diagnostics.